Newsroom

LILLE, Frankrijk--(BUSINESS WIRE)--Alzprotect maakte vandaag bekend dat de Amerikaanse FDA (U.S. Food & Drug Administration) de IND-aanvraag (Investigational New Drug) van het bedrijf heeft goedgekeurd voor AZP2006 (Ezeprogind®) ter behandeling van PSP (progressieve supranucleaire parese). Dankzij de FDA-goedkeuring kan het bedrijf in de Verenigde Staten beginnen met de klinische ontwikkeling van AZP2006. “De FDA IND-goedkeuring is een cruciale stap in ons PSP-programma,” verklaart Philippe...

VANCOUVER, British Columbia--(BUSINESS WIRE)--EverGen Infrastructure Corp. (“EverGen” or the “Company”) (TSXV: EVGN) (OTCQB: EVGIF), today reported financial results as at and for Q1 2026. All amounts are in Canadian dollars and are presented in thousands of dollars unless otherwise stated and have been prepared in accordance with IFRS. Financial Highlights The following table presents EverGen’s Consolidated Financial and Operating Summary:   Three months ended   Mar 31, 2026 Mar 31, 2025 $ Cha...

México, Ciudad de México--(BUSINESS WIRE)--AM Best ha afirmado la Calificación de Fortaleza Financiera de B+ (Buena), la Calificación Crediticia de Emisor de Largo Plazo de “bbb-” (Buena) y la Calificación en Escala Nacional (NSR, por sus siglas en inglés) de México de “aa-.MX” (Superior) de Quálitas Compañía de Seguros S.A. de C.V. (Quálitas) (Ciudad de México, México). Las perspectivas de las Calificaciones Crediticias (calificaciones) son negativas. Al mismo tiempo, AM Best ha retirado estas...

MEXICO CITY--(BUSINESS WIRE)--AM Best has affirmed the Financial Strength Rating of B+ (Good), the Long-Term Issuer Credit Rating of “bbb-” (Good) and the Mexico National Scale Rating of “aa-.MX” (Superior) of Quálitas Compañía de Seguros S.A. de C.V. (Quálitas) (Mexico City, Mexico). The outlook of these Credit Ratings (ratings) is negative. Concurrently, AM Best has withdrawn these ratings as the company has requested to no longer participate in the rating process. The ratings reflect Quálita...

SAN FRANCISCO--(BUSINESS WIRE)--Vector Capital Management, a leading private equity firm specializing in transformational investments in established technology businesses, today announced the successful sale of IPValue Management Group (“IPValue”), a leading IP commercialization provider, to Fortress Investment Group (“Fortress”). Terms of the transaction were not disclosed. Founded in 2001, IPValue is the leading IP commercialization partner to the world’s most innovative technology companies....

LILLE, Francia--(BUSINESS WIRE)--Alzprotect oggi ha reso noto che la Food and Drug Administration (FDA) statunitense ha approvato la domanda di nuovo farmaco sperimentale (IND, Investigational New Drug) della Società per AZP2006 (Ezeprogind®) nel trattamento della Paralisi progressiva sopranucleare (PSP). L'autorizzazione dell'FDA consente alla Società di avviare lo sviluppo clinico di AZP2006 negli Stati Uniti. “L'autorizzazione IND dell'FDA è una tappa cruciale nel nostro programma PSP”, ha d...

LILLE, France--(BUSINESS WIRE)--Alzprotect a annoncé aujourd’hui que la Food and Drug Administration (FDA) des États-Unis avait approuvé la demande d’investigation d’un nouveau médicament de recherche (Investigational New Drug, IND) de la société pour AZP2006 (Ezeprogind®) dans le cadre du traitement de la paralysie supranucléaire progressive (PSP). Cette autorisation de la FDA permet à la société de démarrer le développement clinique d’AZP2006 sur le territoire américain. « L’autorisation de l...

SAN FRANCISCO--(BUSINESS WIRE)--Rubedo Life Sciences, Inc. (Rubedo), een AI-gestuurde, klinische biotech die zich richt op selectieve geneesmiddelen voor celvernieuwing tegen verouderende cellen, heeft vandaag de voorlopige resultaten bekendgemaakt van een fase 1b/2a-onderzoek naar RLS-1496 bij patiënten met actinische keratose (AK). Dit is een veelvoorkomende leeftijdsgebonden aandoening die leidt tot precancereuze huidlaesies en die het meest voorkomt bij mensen ouder dan 65 jaar. Deze bekend...

LILLE, Francia--(BUSINESS WIRE)--Alzprotect anunció hoy que la Administración de Alimentos y Medicamentos (FDA) de los Estados Unidos ha autorizado la solicitud de nuevo fármaco en investigación (IND) de la Empresa de AZP2006 (Ezeprogind®) para el tratamiento de la parálisis supranuclear progresiva (PSP). La autorización de la FDA permite que la Empresa comience el desarrollo clínico de AZP2006 en los Estados Unidos. “La autorización IND de la FDA es un paso fundamental en nuestro programa de P...

PALO ALTO, Calif.--(BUSINESS WIRE)--Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that it will report its first quarter fiscal 2027 financial results after the U.S. financial markets close on Wednesday, June 10, 2026. In conjunction with this report, Navan will host a conference call at 5:00 p.m. Eastern Time (ET) on the same day to discuss the company's financial results and its business operations and outlook. Navan First Quarter Fiscal 2027...